Discover a new way to find and share stories you'll love… Learn about Reading Desk

Post Profile



No difference in death rates among patients exposed to common rheumatoid arthritis drugs

onfirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden—the first to compare mortality rates among patients treated with individual TNF inhibitors—is now available in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).
read more

share

MabThera(rituximab) Is More Effective In Treating Rheumatoid Arthritis Than Switching Patients To A Second Anti-TNF

Health : Medical News Today (7 years ago)

New data1 presented at the European League Against Rheumatism (EULAR) annual meeting revealed that when rheumatoid arthritis (RA) patients do not respond to a TNF inhibitor, a commonly used class of drugs in RA, it is more effective... Read Post

What Is Humira (adalimumab)

Health : Medical News Today (2 years ago)

Humira (adalimumab) is a TNF inhibitor approved for the treatment of rheumatoid arthritis, chronic plaque psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. Humi... Read Post

Rheumatoid Arthritis Drugs: Study Compares Overall Mortality In TNF Inhibitors: Humira, Enbrel, And Remicade

Health : Medical News Today (2 years ago)

New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and in... Read Post


Copyright © 2011 Regator, LLC